nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—epilepsy syndrome	0.452	1	CbGaD
Pimecrolimus—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0237	0.0879	CbGbCtD
Pimecrolimus—CYP3A4—Trimethadione—epilepsy syndrome	0.022	0.0817	CbGbCtD
Pimecrolimus—CYP3A4—Felbamate—epilepsy syndrome	0.022	0.0817	CbGbCtD
Pimecrolimus—CYP3A4—Fosphenytoin—epilepsy syndrome	0.0207	0.0768	CbGbCtD
Pimecrolimus—CYP3A4—Clonazepam—epilepsy syndrome	0.0187	0.0694	CbGbCtD
Pimecrolimus—CYP3A4—Clobazam—epilepsy syndrome	0.018	0.0666	CbGbCtD
Pimecrolimus—CYP3A4—Rufinamide—epilepsy syndrome	0.0153	0.0566	CbGbCtD
Pimecrolimus—CYP3A4—Carbamazepine—epilepsy syndrome	0.0149	0.0552	CbGbCtD
Pimecrolimus—CYP3A4—Primidone—epilepsy syndrome	0.0139	0.0515	CbGbCtD
Pimecrolimus—CYP3A4—Phenytoin—epilepsy syndrome	0.0134	0.0495	CbGbCtD
Pimecrolimus—CYP3A4—Propofol—epilepsy syndrome	0.0125	0.0462	CbGbCtD
Pimecrolimus—CYP3A4—Acetazolamide—epilepsy syndrome	0.0119	0.0441	CbGbCtD
Pimecrolimus—CYP3A4—Phenobarbital—epilepsy syndrome	0.0119	0.0441	CbGbCtD
Pimecrolimus—CYP3A4—Midazolam—epilepsy syndrome	0.0117	0.0435	CbGbCtD
Pimecrolimus—CYP3A4—Diazepam—epilepsy syndrome	0.0113	0.0418	CbGbCtD
Pimecrolimus—CYP3A4—Zonisamide—epilepsy syndrome	0.011	0.0408	CbGbCtD
Pimecrolimus—CYP3A4—Valproic Acid—epilepsy syndrome	0.00889	0.033	CbGbCtD
Pimecrolimus—CYP3A4—Topiramate—epilepsy syndrome	0.00802	0.0297	CbGbCtD
Pimecrolimus—MTOR—forelimb—epilepsy syndrome	0.00697	0.238	CbGeAlD
Pimecrolimus—MTOR—hindbrain—epilepsy syndrome	0.00286	0.0975	CbGeAlD
Pimecrolimus—MTOR—brainstem—epilepsy syndrome	0.00164	0.0559	CbGeAlD
Pimecrolimus—MTOR—forebrain—epilepsy syndrome	0.00158	0.0539	CbGeAlD
Pimecrolimus—MTOR—telencephalon—epilepsy syndrome	0.00145	0.0496	CbGeAlD
Pimecrolimus—FKBP1A—forebrain—epilepsy syndrome	0.00142	0.0485	CbGeAlD
Pimecrolimus—FKBP1A—telencephalon—epilepsy syndrome	0.00131	0.0446	CbGeAlD
Pimecrolimus—Everolimus—MTOR—epilepsy syndrome	0.00112	0.239	CrCbGaD
Pimecrolimus—FKBP1A—medulla oblongata—epilepsy syndrome	0.00103	0.035	CbGeAlD
Pimecrolimus—MTOR—spinal cord—epilepsy syndrome	0.00102	0.0347	CbGeAlD
Pimecrolimus—FKBP1A—midbrain—epilepsy syndrome	0.000938	0.032	CbGeAlD
Pimecrolimus—FKBP1A—spinal cord—epilepsy syndrome	0.000915	0.0312	CbGeAlD
Pimecrolimus—MTOR—head—epilepsy syndrome	0.000905	0.0309	CbGeAlD
Pimecrolimus—MTOR—nervous system—epilepsy syndrome	0.000858	0.0293	CbGeAlD
Pimecrolimus—MTOR—central nervous system—epilepsy syndrome	0.000826	0.0282	CbGeAlD
Pimecrolimus—Sirolimus—FGF2—epilepsy syndrome	0.000815	0.174	CrCbGaD
Pimecrolimus—FKBP1A—head—epilepsy syndrome	0.000814	0.0278	CbGeAlD
Pimecrolimus—MTOR—cerebellum—epilepsy syndrome	0.000807	0.0275	CbGeAlD
Pimecrolimus—FKBP1A—nervous system—epilepsy syndrome	0.000771	0.0263	CbGeAlD
Pimecrolimus—Temsirolimus—MTOR—epilepsy syndrome	0.000755	0.161	CrCbGaD
Pimecrolimus—FKBP1A—central nervous system—epilepsy syndrome	0.000743	0.0253	CbGeAlD
Pimecrolimus—FKBP1A—cerebellum—epilepsy syndrome	0.000726	0.0248	CbGeAlD
Pimecrolimus—Tacrolimus—MTOR—epilepsy syndrome	0.000665	0.142	CrCbGaD
Pimecrolimus—Sirolimus—MTOR—epilepsy syndrome	0.000665	0.142	CrCbGaD
Pimecrolimus—MTOR—brain—epilepsy syndrome	0.000656	0.0224	CbGeAlD
Pimecrolimus—FKBP1A—brain—epilepsy syndrome	0.00059	0.0201	CbGeAlD
Pimecrolimus—CYP3A4—nervous system—epilepsy syndrome	0.000252	0.0086	CbGeAlD
Pimecrolimus—CYP3A4—central nervous system—epilepsy syndrome	0.000243	0.00828	CbGeAlD
Pimecrolimus—Temsirolimus—CYP2D6—epilepsy syndrome	0.000182	0.0389	CrCbGaD
Pimecrolimus—Temsirolimus—ABCB1—epilepsy syndrome	0.00013	0.0278	CrCbGaD
Pimecrolimus—Tacrolimus—ALB—epilepsy syndrome	0.00012	0.0256	CrCbGaD
Pimecrolimus—Tacrolimus—ABCB1—epilepsy syndrome	0.000114	0.0244	CrCbGaD
Pimecrolimus—Sirolimus—ABCB1—epilepsy syndrome	0.000114	0.0244	CrCbGaD
Pimecrolimus—Hypersensitivity—Vigabatrin—epilepsy syndrome	8.85e-05	0.000556	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	8.84e-05	0.000556	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Clonazepam—epilepsy syndrome	8.83e-05	0.000555	CcSEcCtD
Pimecrolimus—Dyspnoea—Lamotrigine—epilepsy syndrome	8.83e-05	0.000555	CcSEcCtD
Pimecrolimus—Angioedema—Valproic Acid—epilepsy syndrome	8.81e-05	0.000553	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Topiramate—epilepsy syndrome	8.81e-05	0.000553	CcSEcCtD
Pimecrolimus—Constipation—Carbamazepine—epilepsy syndrome	8.76e-05	0.00055	CcSEcCtD
Pimecrolimus—Pain—Carbamazepine—epilepsy syndrome	8.76e-05	0.00055	CcSEcCtD
Pimecrolimus—Diarrhoea—Levetiracetam—epilepsy syndrome	8.74e-05	0.000549	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Oxcarbazepine—epilepsy syndrome	8.73e-05	0.000548	CcSEcCtD
Pimecrolimus—Pruritus—Fosphenytoin—epilepsy syndrome	8.72e-05	0.000548	CcSEcCtD
Pimecrolimus—Hypersensitivity—Diazepam—epilepsy syndrome	8.72e-05	0.000548	CcSEcCtD
Pimecrolimus—Malnutrition—Pregabalin—epilepsy syndrome	8.71e-05	0.000548	CcSEcCtD
Pimecrolimus—Pneumonia—Topiramate—epilepsy syndrome	8.65e-05	0.000544	CcSEcCtD
Pimecrolimus—Infestation NOS—Topiramate—epilepsy syndrome	8.6e-05	0.000541	CcSEcCtD
Pimecrolimus—Infestation—Topiramate—epilepsy syndrome	8.6e-05	0.000541	CcSEcCtD
Pimecrolimus—Urticaria—Clonazepam—epilepsy syndrome	8.58e-05	0.000539	CcSEcCtD
Pimecrolimus—Eye disorder—Gabapentin—epilepsy syndrome	8.58e-05	0.000539	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	8.55e-05	0.000537	CcSEcCtD
Pimecrolimus—Abdominal pain—Clonazepam—epilepsy syndrome	8.54e-05	0.000537	CcSEcCtD
Pimecrolimus—Body temperature increased—Clonazepam—epilepsy syndrome	8.54e-05	0.000537	CcSEcCtD
Pimecrolimus—Urticaria—Phenytoin—epilepsy syndrome	8.52e-05	0.000536	CcSEcCtD
Pimecrolimus—Pruritus—Vigabatrin—epilepsy syndrome	8.5e-05	0.000534	CcSEcCtD
Pimecrolimus—Body temperature increased—Phenytoin—epilepsy syndrome	8.48e-05	0.000533	CcSEcCtD
Pimecrolimus—Urticaria—Oxcarbazepine—epilepsy syndrome	8.48e-05	0.000533	CcSEcCtD
Pimecrolimus—Pain—Lamotrigine—epilepsy syndrome	8.47e-05	0.000532	CcSEcCtD
Pimecrolimus—Constipation—Lamotrigine—epilepsy syndrome	8.47e-05	0.000532	CcSEcCtD
Pimecrolimus—Nausea—Acetazolamide—epilepsy syndrome	8.46e-05	0.000531	CcSEcCtD
Pimecrolimus—Body temperature increased—Oxcarbazepine—epilepsy syndrome	8.44e-05	0.00053	CcSEcCtD
Pimecrolimus—Abdominal pain—Oxcarbazepine—epilepsy syndrome	8.44e-05	0.00053	CcSEcCtD
Pimecrolimus—Diarrhoea—Fosphenytoin—epilepsy syndrome	8.44e-05	0.00053	CcSEcCtD
Pimecrolimus—Back pain—Pregabalin—epilepsy syndrome	8.43e-05	0.00053	CcSEcCtD
Pimecrolimus—Cough—Valproic Acid—epilepsy syndrome	8.41e-05	0.000528	CcSEcCtD
Pimecrolimus—Vomiting—Propofol—epilepsy syndrome	8.41e-05	0.000528	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	8.38e-05	0.000526	CcSEcCtD
Pimecrolimus—Pruritus—Diazepam—epilepsy syndrome	8.37e-05	0.000526	CcSEcCtD
Pimecrolimus—Conjunctivitis—Topiramate—epilepsy syndrome	8.36e-05	0.000525	CcSEcCtD
Pimecrolimus—Rash—Propofol—epilepsy syndrome	8.34e-05	0.000524	CcSEcCtD
Pimecrolimus—Dermatitis—Propofol—epilepsy syndrome	8.33e-05	0.000523	CcSEcCtD
Pimecrolimus—Immune system disorder—Gabapentin—epilepsy syndrome	8.29e-05	0.000521	CcSEcCtD
Pimecrolimus—Headache—Propofol—epilepsy syndrome	8.28e-05	0.00052	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Gabapentin—epilepsy syndrome	8.27e-05	0.00052	CcSEcCtD
Pimecrolimus—Hypersensitivity—Zonisamide—epilepsy syndrome	8.26e-05	0.000519	CcSEcCtD
Pimecrolimus—Vomiting—Midazolam—epilepsy syndrome	8.23e-05	0.000517	CcSEcCtD
Pimecrolimus—Diarrhoea—Vigabatrin—epilepsy syndrome	8.22e-05	0.000517	CcSEcCtD
Pimecrolimus—Arthralgia—Valproic Acid—epilepsy syndrome	8.21e-05	0.000516	CcSEcCtD
Pimecrolimus—Rash—Midazolam—epilepsy syndrome	8.16e-05	0.000513	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	8.15e-05	0.000512	CcSEcCtD
Pimecrolimus—Dermatitis—Midazolam—epilepsy syndrome	8.15e-05	0.000512	CcSEcCtD
Pimecrolimus—Urticaria—Carbamazepine—epilepsy syndrome	8.14e-05	0.000511	CcSEcCtD
Pimecrolimus—Vomiting—Levetiracetam—epilepsy syndrome	8.12e-05	0.00051	CcSEcCtD
Pimecrolimus—Epistaxis—Topiramate—epilepsy syndrome	8.11e-05	0.00051	CcSEcCtD
Pimecrolimus—Headache—Midazolam—epilepsy syndrome	8.1e-05	0.000509	CcSEcCtD
Pimecrolimus—Pruritus—Felbamate—epilepsy syndrome	8.1e-05	0.000509	CcSEcCtD
Pimecrolimus—Abdominal pain—Carbamazepine—epilepsy syndrome	8.1e-05	0.000509	CcSEcCtD
Pimecrolimus—Body temperature increased—Carbamazepine—epilepsy syndrome	8.1e-05	0.000509	CcSEcCtD
Pimecrolimus—Diarrhoea—Diazepam—epilepsy syndrome	8.1e-05	0.000509	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	8.1e-05	0.000509	CcSEcCtD
Pimecrolimus—Sinusitis—Topiramate—epilepsy syndrome	8.07e-05	0.000507	CcSEcCtD
Pimecrolimus—Rash—Levetiracetam—epilepsy syndrome	8.05e-05	0.000506	CcSEcCtD
Pimecrolimus—Dermatitis—Levetiracetam—epilepsy syndrome	8.05e-05	0.000506	CcSEcCtD
Pimecrolimus—Headache—Levetiracetam—epilepsy syndrome	8e-05	0.000503	CcSEcCtD
Pimecrolimus—Erythema—Gabapentin—epilepsy syndrome	7.99e-05	0.000502	CcSEcCtD
Pimecrolimus—Malnutrition—Gabapentin—epilepsy syndrome	7.99e-05	0.000502	CcSEcCtD
Pimecrolimus—Angioedema—Pregabalin—epilepsy syndrome	7.96e-05	0.0005	CcSEcCtD
Pimecrolimus—Hypersensitivity—Clonazepam—epilepsy syndrome	7.96e-05	0.0005	CcSEcCtD
Pimecrolimus—Pruritus—Zonisamide—epilepsy syndrome	7.93e-05	0.000498	CcSEcCtD
Pimecrolimus—Hypersensitivity—Phenytoin—epilepsy syndrome	7.91e-05	0.000497	CcSEcCtD
Pimecrolimus—Oedema—Valproic Acid—epilepsy syndrome	7.87e-05	0.000494	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Valproic Acid—epilepsy syndrome	7.87e-05	0.000494	CcSEcCtD
Pimecrolimus—Urticaria—Lamotrigine—epilepsy syndrome	7.86e-05	0.000494	CcSEcCtD
Pimecrolimus—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	7.86e-05	0.000494	CcSEcCtD
Pimecrolimus—Nausea—Propofol—epilepsy syndrome	7.85e-05	0.000493	CcSEcCtD
Pimecrolimus—Vomiting—Fosphenytoin—epilepsy syndrome	7.84e-05	0.000493	CcSEcCtD
Pimecrolimus—Diarrhoea—Felbamate—epilepsy syndrome	7.84e-05	0.000492	CcSEcCtD
Pimecrolimus—Abdominal pain—Lamotrigine—epilepsy syndrome	7.83e-05	0.000492	CcSEcCtD
Pimecrolimus—Body temperature increased—Lamotrigine—epilepsy syndrome	7.83e-05	0.000492	CcSEcCtD
Pimecrolimus—Infection—Valproic Acid—epilepsy syndrome	7.82e-05	0.000491	CcSEcCtD
Pimecrolimus—Rash—Fosphenytoin—epilepsy syndrome	7.77e-05	0.000488	CcSEcCtD
Pimecrolimus—Dermatitis—Fosphenytoin—epilepsy syndrome	7.77e-05	0.000488	CcSEcCtD
Pimecrolimus—Rhinitis—Topiramate—epilepsy syndrome	7.74e-05	0.000486	CcSEcCtD
Pimecrolimus—Back pain—Gabapentin—epilepsy syndrome	7.73e-05	0.000486	CcSEcCtD
Pimecrolimus—Headache—Fosphenytoin—epilepsy syndrome	7.72e-05	0.000485	CcSEcCtD
Pimecrolimus—Nervous system disorder—Valproic Acid—epilepsy syndrome	7.71e-05	0.000485	CcSEcCtD
Pimecrolimus—Nausea—Midazolam—epilepsy syndrome	7.68e-05	0.000483	CcSEcCtD
Pimecrolimus—Diarrhoea—Zonisamide—epilepsy syndrome	7.67e-05	0.000482	CcSEcCtD
Pimecrolimus—Pharyngitis—Topiramate—epilepsy syndrome	7.66e-05	0.000482	CcSEcCtD
Pimecrolimus—Pruritus—Clonazepam—epilepsy syndrome	7.64e-05	0.00048	CcSEcCtD
Pimecrolimus—Vomiting—Vigabatrin—epilepsy syndrome	7.64e-05	0.00048	CcSEcCtD
Pimecrolimus—Skin disorder—Valproic Acid—epilepsy syndrome	7.64e-05	0.00048	CcSEcCtD
Pimecrolimus—Cough—Pregabalin—epilepsy syndrome	7.6e-05	0.000478	CcSEcCtD
Pimecrolimus—Pruritus—Phenytoin—epilepsy syndrome	7.59e-05	0.000477	CcSEcCtD
Pimecrolimus—Nausea—Levetiracetam—epilepsy syndrome	7.59e-05	0.000477	CcSEcCtD
Pimecrolimus—Rash—Vigabatrin—epilepsy syndrome	7.58e-05	0.000476	CcSEcCtD
Pimecrolimus—Dermatitis—Vigabatrin—epilepsy syndrome	7.57e-05	0.000476	CcSEcCtD
Pimecrolimus—Pruritus—Oxcarbazepine—epilepsy syndrome	7.55e-05	0.000475	CcSEcCtD
Pimecrolimus—Hypersensitivity—Carbamazepine—epilepsy syndrome	7.55e-05	0.000474	CcSEcCtD
Pimecrolimus—Headache—Vigabatrin—epilepsy syndrome	7.53e-05	0.000473	CcSEcCtD
Pimecrolimus—Vomiting—Diazepam—epilepsy syndrome	7.52e-05	0.000473	CcSEcCtD
Pimecrolimus—Rash—Diazepam—epilepsy syndrome	7.46e-05	0.000469	CcSEcCtD
Pimecrolimus—Dermatitis—Diazepam—epilepsy syndrome	7.45e-05	0.000468	CcSEcCtD
Pimecrolimus—Arthralgia—Pregabalin—epilepsy syndrome	7.42e-05	0.000466	CcSEcCtD
Pimecrolimus—Headache—Diazepam—epilepsy syndrome	7.41e-05	0.000466	CcSEcCtD
Pimecrolimus—Diarrhoea—Clonazepam—epilepsy syndrome	7.39e-05	0.000464	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	7.37e-05	0.000463	CcSEcCtD
Pimecrolimus—Diarrhoea—Phenytoin—epilepsy syndrome	7.34e-05	0.000461	CcSEcCtD
Pimecrolimus—Nausea—Fosphenytoin—epilepsy syndrome	7.32e-05	0.00046	CcSEcCtD
Pimecrolimus—Diarrhoea—Oxcarbazepine—epilepsy syndrome	7.3e-05	0.000459	CcSEcCtD
Pimecrolimus—Angioedema—Gabapentin—epilepsy syndrome	7.3e-05	0.000459	CcSEcCtD
Pimecrolimus—Hypersensitivity—Lamotrigine—epilepsy syndrome	7.29e-05	0.000458	CcSEcCtD
Pimecrolimus—Vomiting—Felbamate—epilepsy syndrome	7.28e-05	0.000457	CcSEcCtD
Pimecrolimus—Pruritus—Carbamazepine—epilepsy syndrome	7.25e-05	0.000455	CcSEcCtD
Pimecrolimus—Rash—Felbamate—epilepsy syndrome	7.22e-05	0.000454	CcSEcCtD
Pimecrolimus—Eye disorder—Topiramate—epilepsy syndrome	7.22e-05	0.000453	CcSEcCtD
Pimecrolimus—Dermatitis—Felbamate—epilepsy syndrome	7.21e-05	0.000453	CcSEcCtD
Pimecrolimus—Headache—Felbamate—epilepsy syndrome	7.17e-05	0.000451	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	7.17e-05	0.00045	CcSEcCtD
Pimecrolimus—Flushing—Topiramate—epilepsy syndrome	7.17e-05	0.00045	CcSEcCtD
Pimecrolimus—Nausea—Vigabatrin—epilepsy syndrome	7.14e-05	0.000449	CcSEcCtD
Pimecrolimus—Vomiting—Zonisamide—epilepsy syndrome	7.13e-05	0.000448	CcSEcCtD
Pimecrolimus—Oedema—Pregabalin—epilepsy syndrome	7.11e-05	0.000447	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Pregabalin—epilepsy syndrome	7.11e-05	0.000447	CcSEcCtD
Pimecrolimus—Rash—Zonisamide—epilepsy syndrome	7.07e-05	0.000444	CcSEcCtD
Pimecrolimus—Infection—Pregabalin—epilepsy syndrome	7.07e-05	0.000444	CcSEcCtD
Pimecrolimus—Paraesthesia—Valproic Acid—epilepsy syndrome	7.06e-05	0.000444	CcSEcCtD
Pimecrolimus—Dermatitis—Zonisamide—epilepsy syndrome	7.06e-05	0.000444	CcSEcCtD
Pimecrolimus—Nausea—Diazepam—epilepsy syndrome	7.03e-05	0.000442	CcSEcCtD
Pimecrolimus—Headache—Zonisamide—epilepsy syndrome	7.02e-05	0.000441	CcSEcCtD
Pimecrolimus—Dyspnoea—Valproic Acid—epilepsy syndrome	7.01e-05	0.000441	CcSEcCtD
Pimecrolimus—Diarrhoea—Carbamazepine—epilepsy syndrome	7.01e-05	0.00044	CcSEcCtD
Pimecrolimus—Pruritus—Lamotrigine—epilepsy syndrome	7e-05	0.00044	CcSEcCtD
Pimecrolimus—Immune system disorder—Topiramate—epilepsy syndrome	6.98e-05	0.000438	CcSEcCtD
Pimecrolimus—Nervous system disorder—Pregabalin—epilepsy syndrome	6.97e-05	0.000438	CcSEcCtD
Pimecrolimus—Cough—Gabapentin—epilepsy syndrome	6.97e-05	0.000438	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Topiramate—epilepsy syndrome	6.96e-05	0.000437	CcSEcCtD
Pimecrolimus—Skin disorder—Pregabalin—epilepsy syndrome	6.91e-05	0.000434	CcSEcCtD
Pimecrolimus—Vomiting—Clonazepam—epilepsy syndrome	6.87e-05	0.000432	CcSEcCtD
Pimecrolimus—Vomiting—Phenytoin—epilepsy syndrome	6.82e-05	0.000429	CcSEcCtD
Pimecrolimus—Rash—Clonazepam—epilepsy syndrome	6.81e-05	0.000428	CcSEcCtD
Pimecrolimus—Dermatitis—Clonazepam—epilepsy syndrome	6.81e-05	0.000428	CcSEcCtD
Pimecrolimus—Arthralgia—Gabapentin—epilepsy syndrome	6.8e-05	0.000427	CcSEcCtD
Pimecrolimus—Nausea—Felbamate—epilepsy syndrome	6.8e-05	0.000427	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	6.79e-05	0.000427	CcSEcCtD
Pimecrolimus—Vomiting—Oxcarbazepine—epilepsy syndrome	6.79e-05	0.000426	CcSEcCtD
Pimecrolimus—Diarrhoea—Lamotrigine—epilepsy syndrome	6.77e-05	0.000426	CcSEcCtD
Pimecrolimus—Headache—Clonazepam—epilepsy syndrome	6.77e-05	0.000425	CcSEcCtD
Pimecrolimus—Rash—Phenytoin—epilepsy syndrome	6.77e-05	0.000425	CcSEcCtD
Pimecrolimus—Dermatitis—Phenytoin—epilepsy syndrome	6.76e-05	0.000425	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	6.76e-05	0.000424	CcSEcCtD
Pimecrolimus—Rash—Oxcarbazepine—epilepsy syndrome	6.73e-05	0.000423	CcSEcCtD
Pimecrolimus—Pain—Valproic Acid—epilepsy syndrome	6.73e-05	0.000423	CcSEcCtD
Pimecrolimus—Constipation—Valproic Acid—epilepsy syndrome	6.73e-05	0.000423	CcSEcCtD
Pimecrolimus—Dermatitis—Oxcarbazepine—epilepsy syndrome	6.72e-05	0.000422	CcSEcCtD
Pimecrolimus—Headache—Phenytoin—epilepsy syndrome	6.72e-05	0.000422	CcSEcCtD
Pimecrolimus—Erythema—Topiramate—epilepsy syndrome	6.72e-05	0.000422	CcSEcCtD
Pimecrolimus—Malnutrition—Topiramate—epilepsy syndrome	6.72e-05	0.000422	CcSEcCtD
Pimecrolimus—Headache—Oxcarbazepine—epilepsy syndrome	6.69e-05	0.00042	CcSEcCtD
Pimecrolimus—Nausea—Zonisamide—epilepsy syndrome	6.66e-05	0.000418	CcSEcCtD
Pimecrolimus—Oedema—Gabapentin—epilepsy syndrome	6.52e-05	0.00041	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Gabapentin—epilepsy syndrome	6.52e-05	0.00041	CcSEcCtD
Pimecrolimus—Vomiting—Carbamazepine—epilepsy syndrome	6.51e-05	0.000409	CcSEcCtD
Pimecrolimus—Back pain—Topiramate—epilepsy syndrome	6.5e-05	0.000409	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	6.48e-05	0.000407	CcSEcCtD
Pimecrolimus—Infection—Gabapentin—epilepsy syndrome	6.48e-05	0.000407	CcSEcCtD
Pimecrolimus—Rash—Carbamazepine—epilepsy syndrome	6.46e-05	0.000406	CcSEcCtD
Pimecrolimus—Dermatitis—Carbamazepine—epilepsy syndrome	6.45e-05	0.000405	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	6.43e-05	0.000404	CcSEcCtD
Pimecrolimus—Nausea—Clonazepam—epilepsy syndrome	6.42e-05	0.000403	CcSEcCtD
Pimecrolimus—Headache—Carbamazepine—epilepsy syndrome	6.42e-05	0.000403	CcSEcCtD
Pimecrolimus—Nervous system disorder—Gabapentin—epilepsy syndrome	6.4e-05	0.000402	CcSEcCtD
Pimecrolimus—Paraesthesia—Pregabalin—epilepsy syndrome	6.39e-05	0.000401	CcSEcCtD
Pimecrolimus—Nausea—Phenytoin—epilepsy syndrome	6.37e-05	0.0004	CcSEcCtD
Pimecrolimus—Dyspnoea—Pregabalin—epilepsy syndrome	6.34e-05	0.000398	CcSEcCtD
Pimecrolimus—Nausea—Oxcarbazepine—epilepsy syndrome	6.34e-05	0.000398	CcSEcCtD
Pimecrolimus—Skin disorder—Gabapentin—epilepsy syndrome	6.33e-05	0.000398	CcSEcCtD
Pimecrolimus—Vomiting—Lamotrigine—epilepsy syndrome	6.29e-05	0.000395	CcSEcCtD
Pimecrolimus—Urticaria—Valproic Acid—epilepsy syndrome	6.25e-05	0.000393	CcSEcCtD
Pimecrolimus—Rash—Lamotrigine—epilepsy syndrome	6.24e-05	0.000392	CcSEcCtD
Pimecrolimus—Dermatitis—Lamotrigine—epilepsy syndrome	6.24e-05	0.000392	CcSEcCtD
Pimecrolimus—Body temperature increased—Valproic Acid—epilepsy syndrome	6.22e-05	0.000391	CcSEcCtD
Pimecrolimus—Abdominal pain—Valproic Acid—epilepsy syndrome	6.22e-05	0.000391	CcSEcCtD
Pimecrolimus—Headache—Lamotrigine—epilepsy syndrome	6.2e-05	0.00039	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	6.14e-05	0.000386	CcSEcCtD
Pimecrolimus—Nausea—Carbamazepine—epilepsy syndrome	6.08e-05	0.000382	CcSEcCtD
Pimecrolimus—Pain—Pregabalin—epilepsy syndrome	6.08e-05	0.000382	CcSEcCtD
Pimecrolimus—Constipation—Pregabalin—epilepsy syndrome	6.08e-05	0.000382	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	5.94e-05	0.000373	CcSEcCtD
Pimecrolimus—Nausea—Lamotrigine—epilepsy syndrome	5.88e-05	0.000369	CcSEcCtD
Pimecrolimus—Cough—Topiramate—epilepsy syndrome	5.87e-05	0.000369	CcSEcCtD
Pimecrolimus—Paraesthesia—Gabapentin—epilepsy syndrome	5.86e-05	0.000368	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Pregabalin—epilepsy syndrome	5.82e-05	0.000365	CcSEcCtD
Pimecrolimus—Dyspnoea—Gabapentin—epilepsy syndrome	5.81e-05	0.000365	CcSEcCtD
Pimecrolimus—Hypersensitivity—Valproic Acid—epilepsy syndrome	5.8e-05	0.000364	CcSEcCtD
Pimecrolimus—Arthralgia—Topiramate—epilepsy syndrome	5.72e-05	0.00036	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	5.68e-05	0.000357	CcSEcCtD
Pimecrolimus—Urticaria—Pregabalin—epilepsy syndrome	5.65e-05	0.000355	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	5.63e-05	0.000354	CcSEcCtD
Pimecrolimus—Body temperature increased—Pregabalin—epilepsy syndrome	5.62e-05	0.000353	CcSEcCtD
Pimecrolimus—Abdominal pain—Pregabalin—epilepsy syndrome	5.62e-05	0.000353	CcSEcCtD
Pimecrolimus—Pain—Gabapentin—epilepsy syndrome	5.58e-05	0.00035	CcSEcCtD
Pimecrolimus—Constipation—Gabapentin—epilepsy syndrome	5.58e-05	0.00035	CcSEcCtD
Pimecrolimus—Pruritus—Valproic Acid—epilepsy syndrome	5.57e-05	0.00035	CcSEcCtD
Pimecrolimus—Oedema—Topiramate—epilepsy syndrome	5.49e-05	0.000345	CcSEcCtD
Pimecrolimus—Infection—Topiramate—epilepsy syndrome	5.45e-05	0.000342	CcSEcCtD
Pimecrolimus—Diarrhoea—Valproic Acid—epilepsy syndrome	5.38e-05	0.000338	CcSEcCtD
Pimecrolimus—Nervous system disorder—Topiramate—epilepsy syndrome	5.38e-05	0.000338	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Gabapentin—epilepsy syndrome	5.33e-05	0.000335	CcSEcCtD
Pimecrolimus—Skin disorder—Topiramate—epilepsy syndrome	5.33e-05	0.000335	CcSEcCtD
Pimecrolimus—Hypersensitivity—Pregabalin—epilepsy syndrome	5.24e-05	0.000329	CcSEcCtD
Pimecrolimus—Urticaria—Gabapentin—epilepsy syndrome	5.18e-05	0.000326	CcSEcCtD
Pimecrolimus—Abdominal pain—Gabapentin—epilepsy syndrome	5.16e-05	0.000324	CcSEcCtD
Pimecrolimus—Body temperature increased—Gabapentin—epilepsy syndrome	5.16e-05	0.000324	CcSEcCtD
Pimecrolimus—Pruritus—Pregabalin—epilepsy syndrome	5.03e-05	0.000316	CcSEcCtD
Pimecrolimus—Vomiting—Valproic Acid—epilepsy syndrome	5e-05	0.000314	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	5e-05	0.000314	CcSEcCtD
Pimecrolimus—Rash—Valproic Acid—epilepsy syndrome	4.96e-05	0.000312	CcSEcCtD
Pimecrolimus—Dermatitis—Valproic Acid—epilepsy syndrome	4.96e-05	0.000311	CcSEcCtD
Pimecrolimus—Headache—Valproic Acid—epilepsy syndrome	4.93e-05	0.00031	CcSEcCtD
Pimecrolimus—Paraesthesia—Topiramate—epilepsy syndrome	4.93e-05	0.00031	CcSEcCtD
Pimecrolimus—Dyspnoea—Topiramate—epilepsy syndrome	4.89e-05	0.000307	CcSEcCtD
Pimecrolimus—Diarrhoea—Pregabalin—epilepsy syndrome	4.87e-05	0.000306	CcSEcCtD
Pimecrolimus—Hypersensitivity—Gabapentin—epilepsy syndrome	4.8e-05	0.000302	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Topiramate—epilepsy syndrome	4.74e-05	0.000298	CcSEcCtD
Pimecrolimus—Pain—Topiramate—epilepsy syndrome	4.69e-05	0.000295	CcSEcCtD
Pimecrolimus—Constipation—Topiramate—epilepsy syndrome	4.69e-05	0.000295	CcSEcCtD
Pimecrolimus—Nausea—Valproic Acid—epilepsy syndrome	4.67e-05	0.000294	CcSEcCtD
Pimecrolimus—Pruritus—Gabapentin—epilepsy syndrome	4.61e-05	0.00029	CcSEcCtD
Pimecrolimus—Vomiting—Pregabalin—epilepsy syndrome	4.52e-05	0.000284	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Topiramate—epilepsy syndrome	4.49e-05	0.000282	CcSEcCtD
Pimecrolimus—Rash—Pregabalin—epilepsy syndrome	4.48e-05	0.000282	CcSEcCtD
Pimecrolimus—Dermatitis—Pregabalin—epilepsy syndrome	4.48e-05	0.000281	CcSEcCtD
Pimecrolimus—Diarrhoea—Gabapentin—epilepsy syndrome	4.46e-05	0.00028	CcSEcCtD
Pimecrolimus—Headache—Pregabalin—epilepsy syndrome	4.46e-05	0.00028	CcSEcCtD
Pimecrolimus—Urticaria—Topiramate—epilepsy syndrome	4.36e-05	0.000274	CcSEcCtD
Pimecrolimus—Abdominal pain—Topiramate—epilepsy syndrome	4.34e-05	0.000273	CcSEcCtD
Pimecrolimus—Body temperature increased—Topiramate—epilepsy syndrome	4.34e-05	0.000273	CcSEcCtD
Pimecrolimus—Nausea—Pregabalin—epilepsy syndrome	4.22e-05	0.000265	CcSEcCtD
Pimecrolimus—Vomiting—Gabapentin—epilepsy syndrome	4.15e-05	0.000261	CcSEcCtD
Pimecrolimus—Rash—Gabapentin—epilepsy syndrome	4.11e-05	0.000258	CcSEcCtD
Pimecrolimus—Dermatitis—Gabapentin—epilepsy syndrome	4.11e-05	0.000258	CcSEcCtD
Pimecrolimus—Headache—Gabapentin—epilepsy syndrome	4.09e-05	0.000257	CcSEcCtD
Pimecrolimus—Hypersensitivity—Topiramate—epilepsy syndrome	4.04e-05	0.000254	CcSEcCtD
Pimecrolimus—Pruritus—Topiramate—epilepsy syndrome	3.88e-05	0.000244	CcSEcCtD
Pimecrolimus—Nausea—Gabapentin—epilepsy syndrome	3.87e-05	0.000243	CcSEcCtD
Pimecrolimus—Diarrhoea—Topiramate—epilepsy syndrome	3.75e-05	0.000236	CcSEcCtD
Pimecrolimus—Vomiting—Topiramate—epilepsy syndrome	3.49e-05	0.000219	CcSEcCtD
Pimecrolimus—Rash—Topiramate—epilepsy syndrome	3.46e-05	0.000217	CcSEcCtD
Pimecrolimus—Dermatitis—Topiramate—epilepsy syndrome	3.46e-05	0.000217	CcSEcCtD
Pimecrolimus—Headache—Topiramate—epilepsy syndrome	3.44e-05	0.000216	CcSEcCtD
Pimecrolimus—Nausea—Topiramate—epilepsy syndrome	3.26e-05	0.000205	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—epilepsy syndrome	1.94e-05	0.00023	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—epilepsy syndrome	1.94e-05	0.000229	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—epilepsy syndrome	1.93e-05	0.000228	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HBEGF—epilepsy syndrome	1.92e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CHRM1—epilepsy syndrome	1.92e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDYN—epilepsy syndrome	1.92e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GRM1—epilepsy syndrome	1.92e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR7—epilepsy syndrome	1.92e-05	0.000227	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CCR2—epilepsy syndrome	1.91e-05	0.000226	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1RN—epilepsy syndrome	1.9e-05	0.000225	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—DUSP6—epilepsy syndrome	1.9e-05	0.000224	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—TSC2—epilepsy syndrome	1.89e-05	0.000223	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT3—epilepsy syndrome	1.89e-05	0.000223	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TSC2—epilepsy syndrome	1.88e-05	0.000222	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—SRC—epilepsy syndrome	1.87e-05	0.000221	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—epilepsy syndrome	1.85e-05	0.000219	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADAM10—epilepsy syndrome	1.84e-05	0.000218	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APOE—epilepsy syndrome	1.84e-05	0.000218	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—epilepsy syndrome	1.84e-05	0.000218	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—epilepsy syndrome	1.83e-05	0.000217	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—epilepsy syndrome	1.83e-05	0.000217	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—epilepsy syndrome	1.82e-05	0.000216	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—epilepsy syndrome	1.81e-05	0.000215	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6ST—epilepsy syndrome	1.81e-05	0.000214	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GAL—epilepsy syndrome	1.8e-05	0.000213	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GFAP—epilepsy syndrome	1.8e-05	0.000213	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA13—epilepsy syndrome	1.8e-05	0.000213	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—epilepsy syndrome	1.79e-05	0.000211	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP2—epilepsy syndrome	1.78e-05	0.000211	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CHRM3—epilepsy syndrome	1.78e-05	0.000211	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GRM5—epilepsy syndrome	1.78e-05	0.000211	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40—epilepsy syndrome	1.78e-05	0.00021	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PRKCB—epilepsy syndrome	1.74e-05	0.000206	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—S100B—epilepsy syndrome	1.74e-05	0.000206	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6ST—epilepsy syndrome	1.73e-05	0.000204	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SOCS3—epilepsy syndrome	1.73e-05	0.000204	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDC42—epilepsy syndrome	1.72e-05	0.000204	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS2—epilepsy syndrome	1.71e-05	0.000203	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CX3CR1—epilepsy syndrome	1.71e-05	0.000202	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—epilepsy syndrome	1.71e-05	0.000202	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—epilepsy syndrome	1.71e-05	0.000202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—epilepsy syndrome	1.71e-05	0.000202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—epilepsy syndrome	1.69e-05	0.0002	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CX3CL1—epilepsy syndrome	1.68e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BDKRB1—epilepsy syndrome	1.68e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CHRM2—epilepsy syndrome	1.68e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—epilepsy syndrome	1.68e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HBEGF—epilepsy syndrome	1.67e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—epilepsy syndrome	1.67e-05	0.000197	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AVP—epilepsy syndrome	1.67e-05	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FOS—epilepsy syndrome	1.66e-05	0.000196	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC2A1—epilepsy syndrome	1.64e-05	0.000194	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT3—epilepsy syndrome	1.64e-05	0.000194	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—GABBR1—epilepsy syndrome	1.63e-05	0.000193	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—JUNB—epilepsy syndrome	1.63e-05	0.000193	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CASP8—epilepsy syndrome	1.62e-05	0.000191	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS1—epilepsy syndrome	1.62e-05	0.000191	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—epilepsy syndrome	1.58e-05	0.000187	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HES1—epilepsy syndrome	1.58e-05	0.000186	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRH3—epilepsy syndrome	1.56e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HBEGF—epilepsy syndrome	1.54e-05	0.000183	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—OPRM1—epilepsy syndrome	1.54e-05	0.000182	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FYN—epilepsy syndrome	1.53e-05	0.000181	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—H2AFX—epilepsy syndrome	1.53e-05	0.000181	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MEF2C—epilepsy syndrome	1.52e-05	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—S100B—epilepsy syndrome	1.52e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT3—epilepsy syndrome	1.51e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—epilepsy syndrome	1.51e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SOCS3—epilepsy syndrome	1.5e-05	0.000178	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDC42—epilepsy syndrome	1.5e-05	0.000177	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ADAM10—epilepsy syndrome	1.48e-05	0.000175	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—YWHAZ—epilepsy syndrome	1.47e-05	0.000174	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF2—epilepsy syndrome	1.46e-05	0.000173	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NGF—epilepsy syndrome	1.46e-05	0.000172	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR3—epilepsy syndrome	1.45e-05	0.000172	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NPY—epilepsy syndrome	1.42e-05	0.000168	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ATP2A2—epilepsy syndrome	1.42e-05	0.000168	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR5—epilepsy syndrome	1.42e-05	0.000168	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF2—epilepsy syndrome	1.4e-05	0.000166	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF2—epilepsy syndrome	1.4e-05	0.000165	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2—epilepsy syndrome	1.39e-05	0.000164	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HTR2A—epilepsy syndrome	1.39e-05	0.000164	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDC42—epilepsy syndrome	1.38e-05	0.000164	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL18—epilepsy syndrome	1.37e-05	0.000162	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CRH—epilepsy syndrome	1.37e-05	0.000162	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL2—epilepsy syndrome	1.37e-05	0.000162	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL3—epilepsy syndrome	1.37e-05	0.000162	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—OXT—epilepsy syndrome	1.37e-05	0.000162	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HSPB1—epilepsy syndrome	1.37e-05	0.000162	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—L2HGDH—epilepsy syndrome	1.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CERS1—epilepsy syndrome	1.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PDXK—epilepsy syndrome	1.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADK—epilepsy syndrome	1.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GLUD1—epilepsy syndrome	1.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FAR1—epilepsy syndrome	1.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RELA—epilepsy syndrome	1.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FYN—epilepsy syndrome	1.33e-05	0.000158	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MEF2C—epilepsy syndrome	1.33e-05	0.000157	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TSC2—epilepsy syndrome	1.32e-05	0.000156	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGT—epilepsy syndrome	1.32e-05	0.000156	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RELA—epilepsy syndrome	1.3e-05	0.000154	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APOE—epilepsy syndrome	1.29e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—YWHAZ—epilepsy syndrome	1.28e-05	0.000152	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTOR—epilepsy syndrome	1.27e-05	0.000151	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TSC1—epilepsy syndrome	1.27e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTK2B—epilepsy syndrome	1.27e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HES1—epilepsy syndrome	1.27e-05	0.00015	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KDR—epilepsy syndrome	1.26e-05	0.000149	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—epilepsy syndrome	1.26e-05	0.000149	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EPM2A—epilepsy syndrome	1.25e-05	0.000147	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PNPO—epilepsy syndrome	1.25e-05	0.000147	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GAMT—epilepsy syndrome	1.25e-05	0.000147	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NHLRC1—epilepsy syndrome	1.25e-05	0.000147	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTRK2—epilepsy syndrome	1.24e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR2—epilepsy syndrome	1.24e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SST—epilepsy syndrome	1.24e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FYN—epilepsy syndrome	1.23e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—H2AFX—epilepsy syndrome	1.23e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DUSP6—epilepsy syndrome	1.23e-05	0.000145	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PRKCB—epilepsy syndrome	1.22e-05	0.000144	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6ST—epilepsy syndrome	1.21e-05	0.000143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRA2A—epilepsy syndrome	1.21e-05	0.000143	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLAT—epilepsy syndrome	1.2e-05	0.000143	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—JUN—epilepsy syndrome	1.19e-05	0.000141	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—YWHAZ—epilepsy syndrome	1.18e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL12—epilepsy syndrome	1.16e-05	0.000138	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BDKRB2—epilepsy syndrome	1.16e-05	0.000138	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—epilepsy syndrome	1.16e-05	0.000137	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA4—epilepsy syndrome	1.16e-05	0.000137	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—QDPR—epilepsy syndrome	1.16e-05	0.000137	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	1.15e-05	0.000137	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—epilepsy syndrome	1.15e-05	0.000136	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TSC2—epilepsy syndrome	1.15e-05	0.000136	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUNB—epilepsy syndrome	1.14e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CNR1—epilepsy syndrome	1.14e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CCR5—epilepsy syndrome	1.14e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLCB1—epilepsy syndrome	1.14e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR7—epilepsy syndrome	1.11e-05	0.000132	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—POMC—epilepsy syndrome	1.11e-05	0.000131	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COX3—epilepsy syndrome	1.09e-05	0.000129	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL2—epilepsy syndrome	1.08e-05	0.000128	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HBEGF—epilepsy syndrome	1.08e-05	0.000128	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SRC—epilepsy syndrome	1.07e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT3—epilepsy syndrome	1.06e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TSC2—epilepsy syndrome	1.06e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PRKCB—epilepsy syndrome	1.06e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6ST—epilepsy syndrome	1.05e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADAM10—epilepsy syndrome	1.04e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOE—epilepsy syndrome	1.04e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	1.03e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	1.03e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PFKL—epilepsy syndrome	1.03e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	1.03e-05	0.000122	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	1.03e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SRC—epilepsy syndrome	1.02e-05	0.000121	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SRC—epilepsy syndrome	1.02e-05	0.000121	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—S100B—epilepsy syndrome	9.8e-06	0.000116	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF2—epilepsy syndrome	9.79e-06	0.000116	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6ST—epilepsy syndrome	9.72e-06	0.000115	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SOCS3—epilepsy syndrome	9.7e-06	0.000115	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDC42—epilepsy syndrome	9.68e-06	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FOS—epilepsy syndrome	9.65e-06	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—epilepsy syndrome	9.65e-06	0.000114	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UPB1—epilepsy syndrome	9.44e-06	0.000112	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NEU1—epilepsy syndrome	9.44e-06	0.000112	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ATIC—epilepsy syndrome	9.44e-06	0.000112	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—epilepsy syndrome	9.42e-06	0.000111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AVP—epilepsy syndrome	9.37e-06	0.000111	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	9.09e-06	0.000108	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RELA—epilepsy syndrome	9.09e-06	0.000108	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MTOR—epilepsy syndrome	8.91e-06	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HES1—epilepsy syndrome	8.86e-06	0.000105	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GBE1—epilepsy syndrome	8.78e-06	0.000104	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	8.78e-06	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FYN—epilepsy syndrome	8.62e-06	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—H2AFX—epilepsy syndrome	8.59e-06	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MEF2C—epilepsy syndrome	8.57e-06	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF2—epilepsy syndrome	8.52e-06	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—YWHAZ—epilepsy syndrome	8.28e-06	9.8e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	8.26e-06	9.77e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—epilepsy syndrome	8.2e-06	9.7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NGF—epilepsy syndrome	8.19e-06	9.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—epilepsy syndrome	8.09e-06	9.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	8.03e-06	9.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR5—epilepsy syndrome	7.97e-06	9.43e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JUN—epilepsy syndrome	7.96e-06	9.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RELA—epilepsy syndrome	7.91e-06	9.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF2—epilepsy syndrome	7.86e-06	9.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NT5E—epilepsy syndrome	7.83e-06	9.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALAD—epilepsy syndrome	7.83e-06	9.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HTR2A—epilepsy syndrome	7.8e-06	9.22e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—epilepsy syndrome	7.75e-06	9.16e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	7.47e-06	8.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	7.47e-06	8.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TSC2—epilepsy syndrome	7.41e-06	8.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGT—epilepsy syndrome	7.4e-06	8.75e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	7.31e-06	8.64e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOE—epilepsy syndrome	7.25e-06	8.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADSL—epilepsy syndrome	7.16e-06	8.47e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—epilepsy syndrome	7.15e-06	8.45e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—epilepsy syndrome	7.14e-06	8.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—epilepsy syndrome	7.1e-06	8.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—epilepsy syndrome	7.09e-06	8.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GLUL—epilepsy syndrome	7.02e-06	8.3e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—epilepsy syndrome	6.96e-06	8.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JUN—epilepsy syndrome	6.93e-06	8.19e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	6.89e-06	8.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PRKCB—epilepsy syndrome	6.84e-06	8.09e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6ST—epilepsy syndrome	6.81e-06	8.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—epilepsy syndrome	6.63e-06	7.84e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	6.44e-06	7.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—epilepsy syndrome	6.37e-06	7.53e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—epilepsy syndrome	6.34e-06	7.5e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AQP1—epilepsy syndrome	6.26e-06	7.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—POMC—epilepsy syndrome	6.23e-06	7.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—epilepsy syndrome	6.21e-06	7.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL2—epilepsy syndrome	6.09e-06	7.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—epilepsy syndrome	5.74e-06	6.79e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	5.66e-06	6.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	5.66e-06	6.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF2—epilepsy syndrome	5.51e-06	6.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RELA—epilepsy syndrome	5.11e-06	6.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	4.61e-06	5.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—epilepsy syndrome	4.61e-06	5.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	4.49e-06	5.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUN—epilepsy syndrome	4.48e-06	5.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	4.47e-06	5.28e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—epilepsy syndrome	4.44e-06	5.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—epilepsy syndrome	4.36e-06	5.15e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	4.03e-06	4.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—epilepsy syndrome	4.02e-06	4.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—epilepsy syndrome	3.91e-06	4.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—epilepsy syndrome	3.86e-06	4.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	3.84e-06	4.54e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BCHE—epilepsy syndrome	3.82e-06	4.52e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	3.65e-06	4.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	3.61e-06	4.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TH—epilepsy syndrome	3.59e-06	4.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—epilepsy syndrome	3.56e-06	4.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	3e-06	3.55e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAT—epilepsy syndrome	2.96e-06	3.5e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	2.88e-06	3.41e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—epilepsy syndrome	2.68e-06	3.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—epilepsy syndrome	2.5e-06	2.95e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AGT—epilepsy syndrome	2.35e-06	2.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOE—epilepsy syndrome	2.3e-06	2.72e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—POMC—epilepsy syndrome	1.98e-06	2.34e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—epilepsy syndrome	1.8e-06	2.13e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.58e-06	1.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—epilepsy syndrome	7.92e-07	9.37e-06	CbGpPWpGaD
